Prof. Dr. Michael Weller
Risk factors for the development of epilepsy in patients with brain metastases
Wolpert F, Le Rhun E, Imbach L, Poryazova R, Roth P, Neidert M, Grossenbacher B, Terziev R, Lareida A, Weller M. Risk factors for the development of epilepsy in patients with brain metastases. Neuro Oncol 2020; 22:718-728.
Jan 15, 2020Risk factors for the development of epilepsy in patients with brain metastases
Jan 15, 2020Neuro Oncol 2020; 22:718-728
Wolpert Fabian, Le Rhun Emilie, Imbach Lukas L, Poryazova Rositsa, Roth Patrick, Neidert Marian Christoph, Grossenbacher Bettina, Terziev Robert, Lareida Anna, Weller Michael
High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification
Zhu Y, Christiansen A, Fritz C, Rupp N, Poyet C, Rushing E, Weller M, Roth P, Haralambieva E, Hofer S, Chen C, Jochum W, Gao X, Teng X, Chen L, Zhong Q, Wild P, Aebersold R, Ljubicic J, Rutishauser D, Schmid M, Weiss T, Zhang Q, Sun R, Wang B, Yi X, Wu Z, Gao H, Cai X, Ruan G, Zhu T, Xu C, Lou S, Yu X, Gillet L, Blattmann P, Saba K, Fankhauser C, Guo T. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. Mol Oncol 2019; 13:2305-2328.
Sep 18, 2019High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification
Sep 18, 2019Mol Oncol 2019; 13:2305-2328
Zhu Yi, Christiansen Ailsa, Fritz Christine, Rupp Niels J, Poyet Cédric, Rushing Elisabeth, Weller Michael, Roth Patrick, Haralambieva Eugenia, Hofer Silvia, Chen Chen, Jochum Wolfram, Gao Xiaofei, Teng Xiaodong, Chen Lirong, Zhong Qing, Wild Peter J, Aebersold Ruedi, Ljubicic Jelena, Rutishauser Dorothea, Schmid Michael, Weiss Tobias, Zhang Qiushi, Sun Rui, Wang Bo, Yi Xiao, Wu Zhicheng, Gao Huanhuan, Cai Xue, Ruan Guan, Zhu Tiansheng, Xu Chao, Lou Sai, Yu Xiaoyan, Gillet Ludovic, Blattmann Peter, Saba Karim, Fankhauser Christian D, Guo Tiannan
Mutational patterns and regulatory networks in epigenetic subgroups of meningioma
Paramasivam N, Beck K, Brehmer S, Urbschat S, Seiz-Rosenhagen M, Hänggi D, Herold-Mende C, Ketter R, Eils R, Ram Z, Pfister S, Wick W, Weller M, Grossmann R, von Deimling A, Schlesner M, Bewerunge-Hudler M, Schick M, Hübschmann D, Toprak U, Ishaque N, Neidert M, Schrimpf D, Stichel D, Reuss D, Sievers P, Reinhardt A, Wefers A, Jones D, Gu Z, Werner J, Uhrig S, Wirsching H, Sahm F. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathol 2019; 138:295-308.
May 8, 2019Mutational patterns and regulatory networks in epigenetic subgroups of meningioma
May 8, 2019Acta Neuropathol 2019; 138:295-308
Paramasivam Nagarajan, Beck Katja, Brehmer Stephanie, Urbschat Steffi, Seiz-Rosenhagen Marcel, Hänggi Daniel, Herold-Mende Christel, Ketter Ralf, Eils Roland, Ram Zvi, Pfister Stefan M, Wick Wolfgang, Weller Michael, Grossmann Rachel, von Deimling Andreas, Schlesner Matthias, Bewerunge-Hudler Melanie, Schick Matthias, Hübschmann Daniel, Toprak Umut H, Ishaque Naveed, Neidert Marian Christoph, Schrimpf Daniel, Stichel Damian, Reuss David, Sievers Philipp, Reinhardt Annekathrin, Wefers Annika K, Jones David T W, Gu Zuguang, Werner Johannes, Uhrig Sebastian, Wirsching Hans-Georg, Sahm Felix
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393:678-688.
Feb 14, 2019Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Feb 14, 2019Lancet 2019; 393:678-688
Neurooncology Working Group of the German Cancer Society, Simon Matthias, Tonn Jörg-Christian, Stummer Walter, Schaub Christina, Weller Johannes, Kebir Sied, Schäfer Niklas, Stuplich Moritz, Vatter Hartmut, Misch Martin, Keil Vera C, Nelles Michael, Glas Martin, Coch Christoph, Pietsch Torsten, Hattingen Elke, Schmid Matthias, Fimmers Rolf, Weller Michael, Wick Wolfgang, Coenen Martin, Urbach Horst, Vajkoczy Peter, Galldiks Norbert, Bullinger Lars, Goldbrunner Roland, Grauer Oliver, Krex Dietmar, Kortmann Rolf-Dieter, Hau Peter, Sabel Michael, Schlegel Uwe, Steinbach Joachim Peter, Mack Frederic, Tzaridis Theophilos, Schnell Oliver, Bähr Oliver, Renovanz Miriam, Weyerbrock Astrid, Brehmer Stefanie, Suchorska Bogdana, Schmidt-Graf Friederike, Ringel Florian, Kowalski Thomas, Tabatabai Ghazaleh, Seidel Clemens, Uhl Martin, Herrlinger Ulrich
Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
Wolpert F, Preusser M, Kaufmann P, Reyns N, Roth P, Frauenfelder T, Dummer R, Stahel R, Stupp R, Neidert M, Regli L, Andratschke N, Leske H, Petyt G, Füreder L, Rushing E, Berghoff A, Weller M, Le Rhun E. Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. Eur J Cancer 2018; 96:64-72.
Apr 17, 2018Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
Apr 17, 2018Eur J Cancer 2018; 96:64-72
Wolpert Fabian, Preusser Matthias, Kaufmann Philipp Antonio, Reyns Nicolas, Roth Patrick, Frauenfelder Thomas, Dummer Reinhard, Stahel Rolf, Stupp Roger, Neidert Marian Christoph, Regli Luca, Andratschke Nicolaus, Leske Henning, Petyt Gregory, Füreder Lisa Michaela, Rushing Elisabeth, Berghoff Anna Sophie, Weller Michael, Le Rhun Emilie
Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence
Katz L, Baumgarten P, Herold-Mende C, Wick W, Harter P, Weller M, von Deimling A, Snuderl M, Sen C, Wirsching H, Neidert M, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos J, Reuss D, Sahm F. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol 2018; 135:955-963.
Apr 7, 2018Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence
Apr 7, 2018Acta Neuropathol 2018; 135:955-963
Katz Leah M, Baumgarten Peter, Herold-Mende Christel, Wick Wolfgang, Harter Patrick N, Weller Michael, von Deimling Andreas, Snuderl Matija, Sen Chandra, Wirsching Hans-Georg, Neidert Marian Christoph, Hielscher Thomas, Liechty Benjamin, Silverman Joshua, Zagzag David, Sen Rajeev, Wu Peter, Golfinos John G, Reuss David, Sahm Felix
The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy
Neidert M, Rammensee H, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanovic S, Weller M, Wolpert F, Walz J, Kowalewski D, Silginer M, Kapolou K, Backert L, Freudenmann L, Peper J, Marcu A, Wang S, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathol 2018; 135:923-938.
Mar 20, 2018The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy
Mar 20, 2018Acta Neuropathol 2018; 135:923-938
Neidert Marian Christoph, Rammensee Hans-Georg, Henschler Reinhard, Lamszus Katrin, Westphal Manfred, Roth Patrick, Regli Luca, Stevanovic Stefan, Weller Michael, Wolpert Fabian, Walz Juliane Sarah, Kowalewski Daniel Johannes, Silginer Manuela, Kapolou Konstantina, Backert Linus, Freudenmann Lena Katharina, Peper Janet Kerstin, Marcu Ana, Wang Sophie Shih-Yüng, Eisele Günter
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
Beier D, Proescholdt M, Reinert C, Pietsch T, Jones D, Pfister S, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann R, Bogdahn U, Hau P. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro Oncol 2018; 20:400-410.
Feb 19, 2018Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
Feb 19, 2018Neuro Oncol 2018; 20:400-410
Beier Dagmar, Proescholdt Martin, Reinert Christiane, Pietsch Torsten, Jones David T W, Pfister Stefan M, Hattingen Elke, Seidel Clemens, Dirven Linda, Luerding Ralf, Reijneveld Jaap, Warmuth-Metz Monika, Bonsanto Matteo, Bremer Michael, Combs Stephanie E, Rieken Stefan, Herrlinger Ulrich, Kuntze Holger, Mayer-Steinacker Regine, Moskopp Dag, Schneider Thomas, Beringer Andreas, Schlegel Uwe, Stummer Walter, Welker Helmut, Weyerbrock Astrid, Paulsen Frank, Rutkowski Stefan, Weller Michael, Wick Wolfgang, Kortmann Rolf-Dieter, Bogdahn Ulrich, Hau Peter
Bevacizumab: Zankapfel der Glioblastomtherapie
Hundsberger T, Weller M. Bevacizumab: Zankapfel der Glioblastomtherapie. Praxis (Bern 1994) 2017; 106:415-420.
Apr 27, 2017Bevacizumab: Zankapfel der Glioblastomtherapie
Apr 27, 2017Praxis (Bern 1994) 2017; 106:415-420
Hundsberger Thomas, Weller Michael
Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis
Filli L, Weller M, Petersen J, Philipp G, Killeen T, Sutter T, Weller D, Lorincz L, Reuter K, Kapitza S, Zörner B, Linnebank M. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. Neurology 2017; February
Feb 2, 2017Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis
Feb 2, 2017Neurology 2017; February
Filli Linard, Weller Michael, Petersen Jens, Philipp Gruber, Killeen Tim, Sutter Tabea, Weller David, Lorincz Lilla, Reuter Katja, Kapitza Sandra, Zörner Björn, Linnebank Michael
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wick W, Golfinopoulos V, Frenel J, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Roth P, Stupp R, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn M, Steuve J, Brandes A, Hamou M, Wick A, Kosch M, Weller M, Hegi M. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clin Cancer Res 2016; 22:4797-4806.
May 3, 2016Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
May 3, 2016Clin Cancer Res 2016; 22:4797-4806
Wick Wolfgang, Golfinopoulos Vassilis, Frenel Jean-Sebastien, Campone Mario, Ricard Damien, Marosi Christine, Villa Salvador, Weyerbrock Astrid, Hopkins Kirsten, Homicsko Krisztian, Lhermitte Benoit, Pesce Gianfranco, Roth Patrick, Stupp Roger, Gorlia Thierry, Bady Pierre, Platten Michael, van den Bent Martin J, Taphoorn Martin J B, Steuve Jonathan, Brandes Alba A, Hamou Marie-France, Wick Antje, Kosch Markus, Weller Michael, Hegi Monika E
Predicting outcome of epilepsy after meningioma resection
Wirsching H, Morel C, Gmür C, Neidert M, Baumann C, Valavanis A, Rushing E, Krayenbühl N, Weller M. Predicting outcome of epilepsy after meningioma resection. Neuro Oncol 2015; 18:1002-10.
Dec 18, 2015Predicting outcome of epilepsy after meningioma resection
Dec 18, 2015Neuro Oncol 2015; 18:1002-10
Wirsching Hans-Georg, Morel Corinne, Gmür Corinne, Neidert Marian Christoph, Baumann Christian Richard, Valavanis Antonios, Rushing Elisabeth Jane, Krayenbühl Niklaus, Weller Michael
Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells
Wolpert F, Weller M, Westphal M, Lamszus K, Neidert M, Roth P, Deenen R, Florea A, Reifenberger G, Happold C, Eisele G. Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells. PloS one 2015; 10:e0139603.
Oct 6, 2015Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells
Oct 6, 2015PloS one 2015; 10:e0139603
Wolpert Fabian, Weller Michael, Westphal Manfred, Lamszus Katrin, Neidert Marian Christoph, Roth Patrick, Deenen René, Florea Ana-Maria, Reifenberger Guido, Happold Caroline, Eisele Günter
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Korfel A, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Mergenthaler H, Hundsberger T, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 2015; 84:1242-8.
Feb 25, 2015Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Feb 25, 2015Neurology 2015; 84:1242-8
Korfel Agnieszka, Junghanß Christian, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Roth Patrick, Bamberg Michael, Pietsch Torsten, Mergenthaler Hans G, Hundsberger Thomas, Thiel Eckhard, Martus Peter, Möhle Robert, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, Fischer Thomas, Weller Michael
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients
Hundsberger T, Tonder M, Hottinger A, Brügge D, Roelcke U, Putora P, Stupp R, Weller M. Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. J Neurooncol 2014; 118:321-328.
Apr 16, 2014Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients
Apr 16, 2014J Neurooncol 2014; 118:321-328
Hundsberger Thomas, Tonder Michaela, Hottinger Andreas, Brügge Detlef, Roelcke Ulrich, Putora Paul Martin, Stupp Roger, Weller Michael
Immunological challenges for peptide-based immunotherapy in glioblastoma
Mohme M, Neidert M, Regli L, Weller M, Martin R. Immunological challenges for peptide-based immunotherapy in glioblastoma. Cancer Treat Rev 2013; 40:248-58.
Sep 8, 2013Immunological challenges for peptide-based immunotherapy in glioblastoma
Sep 8, 2013Cancer Treat Rev 2013; 40:248-58
Mohme Malte, Neidert Marian Christoph, Regli Luca, Weller Michael, Martin Roland
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 2012; 69:95-101.
Nov 22, 2012Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
Nov 22, 2012Eur Neurol 2012; 69:95-101
Seystahl Katharina, Wiestler Benedikt, Hundsberger Thomas, Happold Caroline, Wick Wolfgang, Weller Michael, Wick Antje
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Hofer S, Wick W, Zander T, Weder P, Roelcke U, Pichler J, Ochsenbein A, Marosi C, Lemke D, Huber U, Hottinger A, Greil R, Elandt K, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011; 50:630-5.
Apr 18, 2011Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Apr 18, 2011Acta Oncol 2011; 50:630-5
Hofer Silvia, Wick Wolfgang, Zander Thilo, Weder Patrik, Roelcke Ulrich, Pichler Josef, Ochsenbein Adrian, Marosi Christine, Lemke Dieter, Huber Urs, Hottinger Andreas F, Greil Richard, Elandt Katarzyna, Weller Michael
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Thiel E, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Leithäuser M, Mergenthaler H, Hundsberger T, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11:1036-47.
Oct 20, 2010High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Oct 20, 2010Lancet Oncol 2010; 11:1036-47
Thiel Eckhard, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Plasswilm Ludwig, Nägele Thomas, Pietsch Torsten, Bamberg Michael, Leithäuser Malte, Mergenthaler Hans-Günther, Hundsberger Thomas, Korfel Agnieszka, Martus Peter, Kanz Lothar, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, von Toll Theda, Weller Michael
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
Herrlinger U, Reifenberger G, Bamberg M, Sommer C, Tan T, Meyermann R, Wick W, Hundsberger T, Steinbach J, Kortmann R, Blaschke B, Loeser S, Koch D, Rieger J, Weller M. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:4412-7.
Sep 20, 2006Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
Sep 20, 2006Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:4412-7
Herrlinger Ulrich, Reifenberger Guido, Bamberg Michael, Sommer Clemens, Tan Ta-Chih, Meyermann Richard, Wick Wolfgang, Hundsberger Thomas, Steinbach Joachim P, Kortmann Rolf-Dieter, Blaschke Britta, Loeser Simon, Koch Dorothee, Rieger Johannes, Weller Michael